



OWL Metabolomics and Sanyal Biotechnology LLC Announce Strategic Partnership with Overseas Expansion

May 04, 2017 – Virginia Beach, Virginia and Amsterdam, Netherlands: Sanyal Biotechnology LLC and One Way Liver S.L. (OWL Metabolomics) have today expanded their existing strategic partnership in order to grow one another's businesses overseas. OWL Metabolomics is planning to open its American office in the VABeachBio biotechnology incubator in Virginia Beach, Virginia, co-locating with Sanyal Biotechnology; likewise, Sanyal Biotechnology is planning to open its European office under the auspices of OWL in its location in Bilbao, Spain. The two companies will share resources in their respective locations as they combine efforts to better serve their pharmaceutical clients. The agreement was made at this week's ILC /EASL Congress in Amsterdam.

OWL and Sanyal Biotechnology have worked closely together in the past providing contract research, particularly in the preclinical NASH market segment, and so their goals and customer bases align closely. The two companies announced in 2016 that OWL would be providing lipidomic and metabolomic profiling services for Sanyal Biotechnology's CRO business, which is focused on drug testing for efficacy and mechanism of action for compounds designed to treat metabolic syndrome, obesity and NAFLD/NASH using the company's proprietary DIAMOND™ mice. OWL has a proprietary diagnostic, the "OWLiver Test", which is the first "in vitro" test for staging steatosis and NASH. The company also develops diagnostic markers research for high prevalence diseases, and offers R&D services in metabolomics and lipidomics to the pharmaceutical, food and cosmetics industries.

"This strategic partnership will help us expand our business in Europe," says Rebecca Caffrey, CEO of Sanyal Biotechnology. "A significant proportion of our customers are European, and by partnering with OWL in Spain we will remove some of the logistical challenges we have faced in serving these customers. Because our business interests are so aligned, we can help one another grow. We also believe that this strategic partnership will result in opportunities for research collaborations with OWL's scientists and the local research institute that will further the development of new products in NASH diagnostics and therapeutics, and create jobs in Spain and back home in the US."

Added OWL's CEO, Pablo Ortiz, MD, PhD:

“OWL Metabolomics and our team of liver research professionals are happy to work with Sanyal Biotechnology. It is very attractive to consider as location enables us to set up our operations in an area which is actively seeking to grow its biotechnology sector, and to develop a core competency in NAFLD and NASH. We believe partner with Sanyal Biotechnology will support future R&D and partnering with other local universities and biotechnology companies.”

About Sanyal Biotechnology

Sanyal Biotechnology is a contract research organization focused on accelerating the search for a cure for NASH. The company has proprietary technology, the DIAMOND™ mouse, which is a superior mouse model for the development of liver diseases that accompany the obesity and Type 2 diabetes epidemics. Sanyal Biotechnology's preclinical drug screening services enable pharmaceutical companies to identify the compounds which are most likely to succeed in human clinical trials, thus shortening the timeline to drug approval.

Sanyal Biotechnology LLC is a privately held company based in Virginia Beach, Virginia. The company was spun out of Virginia Commonwealth University in 2015.

For more information: www.sanyalbio.com

About OWL Metabolomics

OWL Metabolomics is a biotechnology company committed to the identification, validation and global commercialization of diagnostic assays for the liver and other prevalent human diseases, including the identification of potential therapeutic targets involved in the development of such diseases. Since its inception in 2002, OWL has pioneered novel diagnostic research within the fatty liver space.

The 'OWL Liver' and 'OWL Liver Care' assays are the world's first metabolomics-based in-vitro tests for diagnosing NASH and NAFLD, respectively, using micro-blood samples (<0.5 ml) versus today's diagnostic gold-standard which mandates an invasive liver biopsy.

OWL Metabolomics is a privately-held company based in Derio, Spain, and collaborates globally with hospitals, liver research centers, biotechnology groups and the pharmaceutical industry.

More information - <http://www.owlmetabolomics.com/liver-disease-diagnosis.aspx>